What it sells
Stem/progenitor cell therapies for lung and kidney disease.
Business model breakdown
Buyer: who owns the budget?
UnverifiedNot applicable yet: pre-commercial; payer would be patients/health systems if approved.
Trigger: what makes them buy now?
Severe irreversible organ damage (COPD, IPF, CKD) that conventional drugs cannot address.
Workflow: what inputs become what output?
Tissue-specific epithelial progenitor cell therapy (REGEND001 for lung, REGEND003 for kidney) to repair organ structure and function; patients can join clinical trials.
Economics: what it saves and how it charges
UnverifiedClinical-stage biotech; revenue would come from commercializing cell therapy products; none shown.
Distribution: how it reaches customers
Clinical-trial recruitment via a patients center; no commercial channel yet.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| 2026-02-11 | Series C | CNY 350M | 禹泽资本, 合肥高投, 洪泰基金 and others | xhby.net |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.